Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II
Abstract
Purpose
To investigate efficacy of intravitreal injection of pegaptanib and laser photocoagulation for treatment of stage 3+ retinopathy of prematurity (ROP) affecting zone I and posterior zone II, and to compare the results in terms of regression, development of peripheral retinal vessels, and final structural outcome with conventional laser photocoagulation or combined with cryotherapy.
Methods
In a prospective comparative study, 152 eyes with zone I, II posterior ROP 3+ (76 premature rabies), from 2009 to 2011, were included. Patients were randomly assigned to receive intravitreal pegaptanib (Macugen® 0.3 mg = 0.02 mL, Pfizer) with conventional diode laser photocoagulation in group 1 (68 eyes of 34 infants) or only laser therapy combined with cryotherapy in group 2 (84 eyes of 42 infants), bilaterally. The primary outcome of treatment success was defined as absence of recurrence of stage 3+ ROP. The mean follow-up after treatment was 19.3 months in group 1 and 21.5 months in group 2.
Results
Final favorable anatomic outcome and stable regression of ROP at last control examination was noted in 89.7% of eyes in group 1 and 60.8 % of eyes in group 2. Regression of plus disease and peripheral retinal vessels development appeared significantly more rapidly in group 1. No recurrence of neovascularization (stage 3+ ROP) was identified in 85.4% of patients in group 1 and 50% of patients in group 2.
Conclusions
Results of this study support the administration of intravitreal pegaptanib as useful therapy in the management of stage 3+ ROP.
Get full access to this article
View all access and purchase options for this article.
References
Field D.J., Dorling J.S., Manktelow B.N., Draper E.S. Survival of extremely premature babies in a geographically defined population: prospective cohort study of 1994-9 compared with 2000-5. BMJ 2008; 336: 1221–3.
Giannantonio C., Papacci P., Molle F., Lepore D., Gallini F., Romagnoli C. An epidemiological analysis of retinopathy of prematurity over 10 years. J Pediatr Ophthalmol Strabismus 2008; 45: 162–7.
Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008; 84: 77–82.
Katz X., Kychenthal A., Dorta P. Zone I retinopathy of prematurity. J AAPOS 2000; 4: 373–6.
O'Keefe M., Lanigan B., Long V.W. Outcome of zone 1 retinopathy of prematurity. Acta Ophthalmol Scand 2003; 81: 614–6.
Récsán Z., Vámos R., Salacz G. Laser treatment of zone I prethreshold and stage 3 threshold retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2003; 40: 204–7.
Kychenthal A., Dorta P., Katz X. Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 2006; 26(suppl): S11–5.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988; 106: 471–9.
Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 1684–94.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Arch Ophthalmol 1990; 108: 195–204.
Chen J., Smith L.E. Retinopathy of prematurity. Angiogenesis 2007; 10: 133–40.
Smith L.E.H. Through the eyes of a child: understanding retinopathy through ROP: The Friedenwald Lecture. Invest Ophthalmol Vis Sci 2008; 49: 5177–82.
Flynn J.T., Chan-Ling T. Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol 2006; 142: 46–59.
Murata T., Nakagawa K., Khalil A., Ishibashi T., Inomata H., Sueishi K. The temporal and spatial vascular endothelial growth factor expression in retinal vasculogenesis of rat neonates. Lab Invest 1996; 74: 68–77.
Mintz-Hittner H.A., Best L.M. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr 2009; 21: 182–7.
Chung E.J., Kim J.H., Ahn H.S., Koh H.J. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1727–30.
Travassos A., Teixeira S., Ferreira P.et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007; 38: 233–7.
Kusaka S., Shima C., Wada K.et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008; 92: 1450–5.
Honda S., Hirabayashi H., Tsukahara Y., Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1061–3.
Mintz-Hittner H.A., Kuffel R.R. Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II [erratum 2008; 28: 1374]. Retina 2008; 28: 831–8.
Quiroz-Mercado H., Martinez-Castellanos M.A., Hernandez-Rojas M.L., Salazar-Teran N., Chan R.V. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008; 28(suppl): S19–25.
Lee J.Y., Chae J.B., Yang S.J., Yoon Y.H., Kim J-G. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1257–62.
Roohipoor R., Ghassemi H., Ghassemi F.et al. Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. Graefes Arch Clin Exp Ophthalmol 2011; 2489: 1295–301.
Mintz-Hittner H.A., Kennedy K.A., Chuang A.Z. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603–15.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: May 6, 2012
Issue published: September-October 2012
Keywords
PubMed: 22669848
Authors
Metrics and citations
Metrics
Journals metrics
This article was published in European Journal of Ophthalmology.
VIEW ALL JOURNAL METRICSArticle usage*
Total views and downloads: 139
*Article usage tracking started in December 2016
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 46 view articles Opens in new tab
Crossref: 51
- Retinal blood flow velocities in infants with retinopathy of prematuri...
- Polymer-drug conjugates: Origins, progress to date, and future directi...
- Research Progress on Anti-VEGF Drug Ther-apy for Retinopathy of Premat...
- Latest Trends in Retinopathy of Prematurity: Research on Risk Factors,...
- Molecular mechanism of VEGF and its role in pathological angiogenesis
- Retinal microglia protect against vascular damage in a mouse model of ...
- New Aspects on the Treatment of Retinopathy of Prematurity: Currently ...
- RNA-Seq Provides Insights into VEGF-Induced Signaling in Human Retinal...
- New trends in intravitreal anti-VEGF therapy for ROP
- Assessment and management of retinopathy of prematurity in the era of ...
- Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor Af...
- Retinopathy of Prematurity
- Anti-VEGF for Retinopathy of Prematurity
- Description and management of retinopathy of prematurity reactivation ...
- Laser Treatment for Retinopathy of Prematurity
- New opportunities in management of patients with retinopathy prematuri...
- Supplementary material A: Commentaries
- Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopat...
- Efficacy and safety of laser therapy for the treatment of retinopathy ...
- Efficacy of intravitreal aflibercept monotherapy in retinopathy of pre...
- Anti-vascular endothelial growth factor intravitreal therapy for retin...
- Anti-secretogranin III therapy of oxygen-induced retinopathy with opti...
- Polymer–drug conjugate therapeutics: advances, insights and prospects
- A Dosing Study of Bevacizumab for Retinopathy of Prematurity
- Medical and developmental outcomes of bevacizumab versus laser for ret...
- Anti-vascular endothelial growth factor (VEGF) drugs for treatment of ...
- Retinopathy of Prematurity
- Retinopathy of Prematurity
- Effect of Intravitreal Aflibercept on Central Retinal Arterial Blood F...
- Low-dose ranibizumab as primary treatment of posterior type I retinopa...
- Anti–Vascular Endothelial Growth Factor Medications in Retinopathy of ...
- Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment ...
- Anti-VEGF for ROP and Pediatric Retinal Diseases
- Anti–Vascular Endothelial Growth Factor and the Evolving Management Pa...
- Pharmacotherapy and ROP: Going Back to the Basics
- Modern approach to the retinopathy of prematurity treatment
- Retinopathy of Prematurity
- Current perspective on retinopathy of prematurity
- Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity
- Anti-vascular endothelial growth factor (VEGF) drugs for treatment of ...
- Retinopathy of Prematurity
- Retinopathy of prematurity: Past, present and future
- A new modified technique for the treatment of high-risk prethreshold R...
- A Systematic Review and Meta-Analysis on the Safety of Vascular Endoth...
- Retinopathy of prematurity: recent developments in diagnosis and treat...
- Intravitreal Anti-VEGF Therapy as a Treatment for Retinopathy of Prema...
- Structural, Visual and Refractive Outcomes of Intravitreal Aflibercept...
- Confluent Diode Laser Coagulation: The Gold Standard of Therapy for Re...
- Risk Factors for Retinopathy of Prematurity: Beyond Age, Birth Weight,...
- Aktuelle Therapieoptionen bei Frühgeborenenretinopathie
- Treatment of retinopathy of prematurity with vascular endothelial grow...
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
SCALA members can access this journal content using society membership credentials.
SCALA members can access this journal content using society membership credentials.
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
